<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The no-reflow phenomenon has been produced in the cerebral hemispheres of the gerbil by 30 minutes of bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The no-reflow phenomenon was found to develop in relation to the fall in blood pressure which occurred on release of bilateral carotid clips </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="6794">Metaraminol</z:chebi> <z:chebi fb="1" ids="15193,50562">tartrate</z:chebi> intravenously prevented the fall of blood pressure and significantly reduced the occurrence of the no-reflow phenomenon </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="6794">Metaraminol</z:chebi> <z:chebi fb="1" ids="15193,50562">tartrate</z:chebi>, however, did not alter the morbidity or mortality of carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 30 minutes </plain></SENT>
<SENT sid="4" pm="."><plain>There is thus no support from these experiments for the view that the no-relow phenomenon plays an important functional role in the reversibility of the effects of severe <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
</text></document>